A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of the agent by patients with HER2-low or HER2-utralow metastatic breast cancer whose disease progressed after at least one endocrine therapy.

In a bombshell announcement made last week, the Food and Drug Administration (FDA) said it will ban the use of FD&C Red No. 3, a synthetic food dye, from the nation’s food supply. The latest initiative comes more than three decades after the colorant was barred from cosmetics and non-oral medications due to potentially causing cancer.

The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ahead of chemotherapy in a variety of tumors.

A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the spread of brain proteins believed to be responsible for Parkinson's

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.

FDA officials have telegraphed the decision for months. While the agency has long said that it did not think evidence of Red 3 causing cancer applied to humans, officials said their hand was forced by a law requiring the agency to pull additives that are cancerous in animals.

After decades of debate, the Food and Drug Administration (FDA) has announced a ban on Red Dye No. 3, a synthetic food coloring that’s been linked to cancer in male lab rats. The decision comes after a petition filed in 2022 by advocacy groups,

The U.S. Food and Drug Administration has officially banned red dye — called Red 3, or Erythrosine — from foods, dietary supplements and ingested medicines, as reported on Wednesday.

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results.

Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical cancer.

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.